Recent Advances in Hodgkin's Lymphoma Treatment in Children

Efficacy

In Children and Adolescents, Improved Early Tumor Control with Increased-dose BEACOPP

  • Study assessed 99 previously untreated children 4 to 20 years of age (median age 14 years; 50% male) with advanced Hodgkin's lymphoma undergoing induction therapy.1
  • Children's Oncology group pilot study; median follow-up 6 months.1

  • Rapidity of response defined as > 70% reduction in disease burden

Reference:

  1. Kelly KM, Hutchinson RJ, Sposto R, et al. Feasibility of upfront dose-intensive chemotherapy in children with advanced-stage Hodgkin's lymphoma: preliminary results from the Children's Cancer Group Study CCG-59704. Ann Oncol. 2002;13(suppl 1):107-111.

Back To Top

Important Safety Information

WARNING
It is recommended that MATULANE be given only by or under the supervision of a physician experienced in the use of potent antineoplastic drugs. Adequate clinical and laboratory facilities should be available to patients for proper monitoring of treatment.

Matulane is contraindicated in patients with known hypersensitivity to the drug or inadequate marrow reserve as demonstrated by bone marrow aspiration. Due consideration of this possible state should be given to each patient who has leukopenia, thrombocytopenia, or anemia.

Matulane in combination therapy is a potent chemotherapeutic agent. Before prescribing Matulane, the sections in the Prescribing Information concerning usage in pregnancy, occurrence of secondary cancers, monitoring required in liver and kidney disease, hematologic effects, CNS effects, and potentiation associated with alcohol and MAO inhibitors should be carefully evaluated.

Please see full Prescribing Information for Matulane indications and usage, contraindications, and warnings including boxed WARNINGS, precautions, and adverse reactions.